UBS raised the firm’s price target on Neurocrine (NBIX) to $152 from $137 and keeps a Buy rating on the shares. Neurocrine’s print should rest the crowded bear case into the quarter and remove a key overhang for the stock, and believes the shares will be “particularly attractive” from here, the analyst tells investors in a research note. UBS says the Ingrezza growth narrative is now re-established, and its analysis suggests Crenessity peak sales of $2.5B.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $165 from $155 at Guggenheim
- Neurocrine price target raised to $183 from $179 at BofA
- Cautious Outlook for Neurocrine Amid Cinecerfont Launch Success and Earnings Challenges
- Neurocrine price target raised to $160 from $158 at Canaccord
- Neurocrine price target lowered to $154 from $160 at Piper Sandler